Allogene Therapeutics, Inc. Common Stock

ALLONASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
1.74 USD
↗ 0.02 (0.87%)🟢PRE MARKET (AS OF 05:13 AM EDT)
🟢Market: OPEN

Allogene Therapeutics, Inc. Common Stock (ALLO) trades at $1.74 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, ALLO trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Sep 15, 2026.

Open?$1.74
High?$1.74
Low?$1.74
Prev. Close?$1.72
Volume?284
Avg. Volume?5.0M
VWAP?$1.74
Rel. Volume?0.00x
Bid / Ask
Bid?$1.47 × 100
Ask?$2.06 × 100
Spread?$0.59
Midpoint?$1.77
Valuation & Ratios
Market Cap?594.2M
Shares Out?345.5M
Float?274.9M
Float %?79.6%
P/E Ratio?N/A
P/B Ratio?1.36
EPS?-$0.48
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
152
Market Cap
615.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.allogene.com
Listed
2018-10-11
Address
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
65
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?-2.61Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?21.50%Squeeze Risk
Short Interest?59.1M
Days to Cover?12.2
Free Float274.9M
Avg Daily Volume4.9M
Settlement Date2026-08-31
Financial Health
Current Ratio?10.72Strong
Quick Ratio?10.72Strong
Cash Ratio?1.22Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
90
1.36CHEAP▾
P/S?
Peers
100
S&P
3
128.07HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.3CHEAP▾
EV/Sales?
Peers
100
S&P
3
119.75HIGH▾
Returns & Efficiency
ROE?
S&P
3
-37.9%WEAK▾
ROA?
S&P
3
-30.1%WEAK▾
Cash Flow & Enterprise
FCF?$-102598000
Enterprise Value?$555.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist